In a nation where science and medical advances have significantly raised the bar on modern healthcare, American consumers have come to expect quality prevention, diagnostic and treatment options. With innovative medicines comes relief, healing and sometimes cures, but with a big price tag to both individuals and the health care system. Drug innovation is based on research that begins in the lab and moves through the development and testing process all the way to the end-run: FDA-approved medicines that are safe and effective for their intended use.
Drug development– and all of the research that it requires– is a long and arduous process, but the final products provide value in many ways. As patients and consumers, we measure the impact of medicines by improvement in our quality of life, but do we give thought to the economic value that medicines bring to society as a whole?
One of the world’s largest health care companies, Pfizer, has worked hard to provide patients and clinicians with data to show that medicines do provide tremendous value to both individuals and society. In a series of papers, called “Value of Medicines,” they have taken a look at a host of health conditions, such as psoriasis, rheumatoid arthritis and others, and addressed the economic impact of medications used to treat them. They also have examined the economics of general health measures, such as vaccines and drug adherence.
The data for the series come from published, peer-reviewed studies and the papers are brief and easy to access. We think the series will provide you with a deeper understanding of the value of medicines. Follow the link for a full list of downloadable papers and colorful infographics that make the content easy to understand: www.pfizer.com/valueofmedicines. Also, find more information on Twitter at #valueofmeds.